title: Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.
abstract: As populations age, the prevalence of geriatric neurodegenerative diseases will increase. These diseases generally are multifactorial, arising from complex interactions among genes, environment, concurrent morbidities, treatments, and time. This essay provides a concept for the pathogenesis of Lewy body diseases such as Parkinson disease, by considering them in the context of allostasis and allostatic load. Allostasis reflects active, adaptive processes that maintain apparent steady states, via multiple interacting effectors regulated by homeostatic comparators-"homeostats." Stress can be defined as a condition or state in which a sensed discrepancy between afferent information and a setpoint for response leads to activation of effectors, reducing the discrepancy. "Allostatic load" refers to the consequences of sustained or repeated activation of mediators of allostasis. From the analogy of an idling car, the revolutions per minute of the engine can be maintained at any of a variety of levels (allostatic states). Just as allostatic load (cumulative wear and tear) reflects design and manufacturing variations, byproducts of combustion, and time, eventually leading to engine breakdown, allostatic load in catecholaminergic neurons might eventually lead to Lewy body diseases. Central to the argument is that catecholamines in the neuronal cytoplasm are autotoxic and that catecholamines from storage visicles leak into the cytoplasm continuously during life. These neurons therefore depend on vesicular sequestration to limit autotoxicity of cytosolic transmitter. Parkinson disease might be a disease of the elderly because of allostatic load, which depends on genetic predispositions, environmental exposures, repeated stress-related catecholamine release, and time.
authors: Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1620, USA. goldsteind@ninds.nih.gov
authors: D S
authors: DS
authors: Goldstein
references: Ann N Y Acad Sci. 2004 Jun;1018:224-30
references: 15240373
references: Acta Neuropathol. 2008 Feb;115(2):193-203
references: 17965867
references: Ann Intern Med. 2001 Dec 4;135(11):1010-1
references: 11730415
references: Mov Disord. 2008 Sep 15;23(12):1725-32
references: 18661549
references: Eur J Neurol. 2011 May;18(5):703-10
references: 21073636
references: Nature. 1997 Aug 28;388(6645):839-40
references: 9278044
references: Semin Neurol. 2003 Dec;23(4):351-63
references: 15088256
references: Eur J Neurosci. 2007 Dec;26(11):3104-12
references: 18005066
references: Chem Res Toxicol. 2009 May;22(5):835-41
references: 19388687
references: Brain. 2004 Apr;127(Pt 4):768-72
references: 14736756
references: J Neurosci. 2006 Sep 6;26(36):9304-11
references: 16957086
references: Klin Wochenschr. 1960 Dec 15;38:1236-9
references: 13726012
references: PLoS One. 2010 Dec 13;5(12):e15251
references: 21179455
references: Pharmacol Rev. 2004 Sep;56(3):331-49
references: 15317907
references: Science. 2007 Oct 19;318(5849):426-30
references: 17947576
references: Chem Res Toxicol. 2009 Jul;22(7):1256-63
references: 19537779
references: Neuron. 2009 Apr 30;62(2):218-29
references: 19409267